Scipio bioscience, a Paris, France-based biotechnology company developing a new generation of single-cell sequencing solutions, secured a €6.0 M Series A financing.

The funding will accelerate the final development of its single-cell RNA-sequencing kit, as well as marketing and business development efforts to prepare for commercial launch in 2022.

Co-founded and led by Pierre Walrafen, PhD, CEO, and world-renowned biophysicist Prof Stuart Edelstein, President, Scipio bioscience develops a new generation of single-cell sequencing solutions, to answer the needs of clinical and basic research labs.

Scipio bioscience was supported by a grant from the Région Île-de-France and the Programme d’Investissement d’Avenir, operated by BPI France.

FinSMEs25/02/2020 | To read full story, visit https://startuparound.com/read/1582626713.9481783/Scipio-bioscience-Secures-€6.0M-Series-A-Financing?ref=audio_experience